Xenon Pharmaceuticals, Inc.
Industry Group: Pharmaceuticals
Country/Region: Canada
Identifier: NAS:XENE
Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada.
ESG Risk Rating
Ranking
Industry Group (1st = lowest risk)
Pharmaceuticals 329 out of 851
Universe
Global Universe 9165 out of 15104
What are the ESG Risk Ratings?
Notice: The information is provided as is, for informational, non-commercial purposes only, does not constitute investment advice and is subject to conditions available in our Legal Disclaimer. They are not directed to, or intended for distribution to or use by India-based clients or users and their distribution to Indian resident individuals or entities is not permitted. Usage of this information is not permitted in any way, unless otherwise agreed in writing. By way of exception, usage of this information is permitted to the non-India based rated subjects, limited to a single reference to the score on the rated subject’s sustainability webpage or CSR report, mentioning Sustainalytics as a source. For referencing Sustainalytics please consult the Company Guide.
Industry Comparison
Company | ESG Risk Rating | Industry Rank |
---|---|---|
PTC Therapeutics, Inc. |
22.6
Medium
|
130 out of 851 |
Arrowhead Pharmaceuticals, Inc. |
25.8
Medium
|
223 out of 851 |
Walvax Biotechnology Co., Ltd. |
26.9
Medium
|
277 out of 851 |
Xenon Pharmaceuticals, Inc. |
27.7
Medium
|
329 out of 851 |
Vera Therapeutics, Inc. |
35.3
High
|
669 out of 851 |
For corporate professionals interested in direct competitor insights
Sustainalytics' Peer Performance Insights gives an in-depth analysis of your company's ESG strengths and weaknesses compared to your competitors and industry performance. These insights can be used to identify areas of ESG improvement to help inform future management decisions that align with your organization's sustainability goals.
Our Approach to Calculating ESG Risk
The ESG Risk Ratings measure a company's exposure to industry-specific material ESG risks and how well a company is managing those risks.
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues. Our exposure score takes into consideration subindustry and company-specific factors such as its business model.
Xenon Pharmaceuticals, Inc.'s Exposure is Medium
Management
Management refers to how well a company is managing its relevant ESG issues. Our management score assesses the robustness of a company's ESG programs, practices and policies.
Xenon Pharmaceuticals, Inc.'s Management of ESG Material Risk is Average